Cargando…

Durvalumab-induced diabetic ketoacidosis followed by hypothyroidism

SUMMARY: Durvalumab is a programmed cell death ligand 1 inhibitor, which is now approved in Australia for use in non-small-cell lung and urothelial cancers. Autoimmune diabetes is a rare immune-related adverse effect associated with the use of immune checkpoint inhibitor therapy. It is now being inc...

Descripción completa

Detalles Bibliográficos
Autores principales: Patel, Shivani, Chin, Venessa, Greenfield, Jerry R
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Bioscientifica Ltd 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6935712/
https://www.ncbi.nlm.nih.gov/pubmed/31829972
http://dx.doi.org/10.1530/EDM-19-0098